GlassScriptPhysician profile
Melissa M Stoner
NPI 1265687875
$2,747.61
in general payments reported to CMS, 2019-2025
23 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $115 · 2021: $22.86 · 2022: $91.27 · 2023: $341 · 2024: $394 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $535.17 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $504.92 | 2023-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $296.76 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $272.98 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $222.67 | 2019-2025 | |
| Allergan, INC. | $209.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.41 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $81.15 | 2019-2024 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $69.69 | 2025 | Voquezna |
| Exact Sciences Corporation | $62.10 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $58.15 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.75 | 2019-2020 | |
| Mylan Specialty L.P. | $36.35 | 2022-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $32.43 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.82 | 2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.89 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $18.74 | 2025 | |
| Gilead Sciences, INC. | $18.08 | 2019 | |
| Amgen INC. | $17.63 | 2025 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $17.30 | 2019 | |
| Shire North American Group INC | $16.34 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.43 | 2021 | |
| Hikma Pharmaceuticals USA | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Stoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.